[90Y]Y-PentixaTher

DRUG3 trials

Sponsors

Pentixapharm AG, Klinikum rechts der Isar der TU Muenchen AöR

Conditions

CNS LymphomaCentral nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondaryNon-Hodgkin lymphomas (NHL)

Phase 1

[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

RecruitingNCT06132737

Pentixapharm AGCNS Lymphoma

Start: 2023-11-07End: 2028-03-26Target: 15Updated: 2025-01-13

An open-label dose escalation study to evaluate safety, tolerability, biodistribution and efficacy of [90Y]Y-PentixaTher for the therapy of recurrent or refractory primary or isolated secondary central nervous system lymphoma

RecruitingCTIS2024-512097-98-00

Pentixapharm AGCentral nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

Start: 2023-11-07Target: 15Updated: 2026-01-27

CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY

Not yet recruitingCTIS2024-517639-35-00

Klinikum rechts der Isar der TU Muenchen AöRNon-Hodgkin lymphomas (NHL)

Target: 38Updated: 2024-10-14